Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc/ CA05156V1022 /
AUPH
|
06.06.2024 22:00:00
|
Diff.
-0,0700
|
Volumen |
Geld22:04:40 |
Brief22:04:40 |
Tageshoch |
Tagestief |
|
5,3900USD
|
-1,28%
|
741.128
Umsatz: 3,26 Mio. |
5,3800Geld Vol: 100 |
5,4900Brief Vol: 200 |
5,4900 |
5,3500 |
Unternehmensportrait
Aurinia Pharmaceuticals Inc. develops and commercializes therapies for diseases with unmet medical needs. Its product, LUPKYNIS, treats active lupus nephritis. Headquartered in Victoria, Canada, it collaborates with Otsuka Pharmaceutical Co., Ltd.
Vorstand & Aufsichtsrat
| Vorstandsvorsitzender |
| Peter Greenleaf |
| Vorstand |
| Joe Miller, Max Donley , Sue Evans, Scott Habig, Volker Knappertz, Michael Martin , Stephen Robertson |
| Aufsichtsrat |
| R. Hector MacKay-Dunn, Jill Leversage, Jeffrey A. Bailey, Brinda Balakrishnan, Daniel G. Billen, Dr. Robert T. Foster, Peter Greenleaf, David R.w. Jayne, Dr. Karen Smith |
Unternehmensinformationen
| Name: |
Aurinia Pharmaceuticals Inc. |
| Adresse: |
#140, 14315 – 118 Avenue,Edmonton, AB T5L 4S6 |
| Telefon: |
+1-250-744-2487 |
| Fax: |
+1-250-708-4345 |
| E-Mail: |
-
|
| Internet: |
https://www.auriniapharma.com/ |
| Industrie: |
Gesundheitswesen |
| Sektor: |
Pharmazeutische Industrie |
| Sub-Sektor: |
Pharmazeutische Industrie |
| Ende des Finanzjahres: |
31.12 |
| Streubesitz: |
92,79% |
| IPO Datum: |
- |
